Cerebrospinal fluid (CSF) samples are increasingly being used for genomic profiling of brain tumors, offering a less invasive alternative to tissue biopsies. CSF samples provide a higher signal-to-noise ratio for detecting tumor-derived cell-free DNA (cfDNA) compared to plasma samples, making them particularly useful for …
ASCO to shine light on multimodal AI models: Plus, melanoma diagnostics and gastroesophageal cancer targets
The upcoming ASCO 2026 meeting will focus on the clinical application of AI in cancer care, emphasizing multimodal AI models that integrate pathology, radiology, molecular data, and liquid biopsy.
SPONSORED ROUNDTABLES
Thermo Fisher Scientific’s SwiftArrayStudio microarray analyzer was developed in response to customer needs for simpler workflows, more consistent turnaround times, and lower operational burden in genomics labs.
CAP TODAY RECOMMENDS
February 2026—Prepared with expert insight from Anil Parwani, MD, PhD; Scott Hammond; and Melinda Schumacher, MD, Grundium’s white paper describes, from a pathologist’s perspective, how compact WSI systems can shorten consult turnaround times and reduce variability, improve access to subspecialty review without adding travel or courier burden, enhance community pathologists’ professional satisfaction and confidence, support scalable, secure, and validated workflows and lay the foundation for AI and advanced analytics as digital adoption grows. Download the white paper here.
Interactive Product Guides
Use our comprehensive guides to view and compare instruments and software systems feature by feature.
FEATURED GUIDE: Billing
Laboratory and pathology billing face challenges from reimbursement threats, downcoding, denials, and prior authorizations.
PRODUCT GUIDE ROUNDTABLES
MARKETPLACE
July 2025—Labcorp has expanded its precision oncology portfolio with its Labcorp Plasma Detect, to help assess the risk of disease recurrence in stage three colon cancer patients, and PGDx Elio Plasma Focus Dx, a kitted, pan-solid tumor liquid biopsy test authorized by the FDA to identify patients who may benefit from targeted treatments.